Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00818961 · ClinicalTrials.gov registry record · Phase 2
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
A Phase 2 study, sponsored by Northside Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00818961 is a Phase 2 study that was terminated before completion, run by Northside Hospital. The registered enrollment target is 36 participants.
The verdict
NCT00818961, a Phase 2 study, was terminated before completion, sponsored by Northside Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving a monoclonal antibody, such as alemtuzumab, before transplant and tacrolimus and methotrexate after transplant may stop this from happening. PURPOSE: This phase II trial is studying the side effects of donor stem cell transplant and to see how well it works in treating patients with high-risk hematologic cancer.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- BIOLOGICAL alemtuzumab
- DRUG busulfan
- BIOLOGICAL graft-versus-tumor induction therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00818961
The ClinicalTrials.gov registry entry for NCT00818961 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northside Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00818961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00818961 about?
NCT00818961 is a clinical study titled "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer". RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining canc...
What is the current status of trial NCT00818961?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2005-05. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00818961?
The interventions under investigation include: cyclophosphamide (DRUG), rituximab (BIOLOGICAL), alemtuzumab (BIOLOGICAL), busulfan (DRUG), graft-versus-tumor induction therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00818961?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.